Feasibility and safety of adoptive immunotherapy with ex vivo-generated autologous, cytotoxic T lymphocytes in patients with solid tumor

Cytotherapy

Volumn 14, Issue 1, 2012, Pages 80-90

  Montagna, Daniela ^a   Turin, Ilaria ^a   Schiavo, Roberta ^b   Montini, Enrica ^a   Zaffaroni, Nadia ^c   Villa, Raffaella ^c   Secondino, Simona ^b   Schiavetto, Ilaria ^b   Caliogna, Laura ^a   Locatelli, Franco ^a,d   Libri, Virginia ^e   Pession, Andrea ^e   Tonelli, Roberto ^e   Maccario, Rita ^a   Siena, Salvatore ^b   Pedrazzoli, Paolo ^a,b,f  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b OSPEDALE NIGUARDA CA GRANDA   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^e UNIVERSITY OF BOLOGNA   (Italy)

^f Gruppo Ital di Trapianto di Midollo Cellule Staminali Ematopoietiche e Terapia Cellulare (GITMO)   (Italy)

Author keywords

adoptive T cell therapy; autologous tumor cells; cytotoxic T lymphocytes; lymphodepletion; solid tumors

Indexed keywords

CYCLOPHOSPHAMIDE; FLUDARABINE; INTERLEUKIN 2; TELOMERASE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER PATIENT; CELL PROLIFERATION; CLINICAL ARTICLE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG ERUPTION; DRUG FEVER; DRUG SAFETY; ENDOMETRIUM SARCOMA; EX VIVO STUDY; FEASIBILITY STUDY; FEMALE; FEVER; FOLLOW UP; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; KIDNEY SARCOMA; LOW DRUG DOSE; MALE; MYALGIA; NEUROECTODERM TUMOR; PERIPHERAL BLOOD MONONUCLEAR CELL; PERIPHERAL NEUROECTODERMAL TUMOR; PRIORITY JOURNAL; TELOMERE; TUMOR CELL;

EID: 83755229580     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.3109/14653249.2011.610303     Document Type: Article

References (32)

1. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: A clinical path to effective cancer immunotherapy. Nat Rev Cancer. 2008;8: 299-308. (Pubitemid 351430867)
2. Dudley ME, Rosenberg SA. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer. 2003;3:666-75. (Pubitemid 37328821)
3. Yang JC, Childs R. Immunotherapy for renal cell cancer. J Clin Oncol. 2006;24:5576-83. (Pubitemid 46631338)
4. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002;298:850-4. (Pubitemid 35231542)
5. Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005;23:2346-57. (Pubitemid 46218728)
6. 8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci USA. 2002;99:16168-73. (Pubitemid 35462767)
7. Yee J, Thompson JA, Roche P, Byrd DR, Lee PP, Piepkorn M, et al. Melanocyte destruction after antigenspecifi c immunotherapy of melanoma: Direct evidence of T cell-mediated vitiligo. J Exp Med. 2000;192:1637-44.
8. 8+ T cells for the treatment of patients with metastatic melanoma. J Clin Oncol. 2006;24: 5060-9. (Pubitemid 46631410)
9. Blasco MA. Telomerase beyond telomeres. Nat Rev Cancer. 2002;2:627-33.
10. Weng NP, Palmer LD, Levine BL, Lane HC, June CH, Hodes RJ. Tales of tails: regulation of telomere length and telomerase activity during lymphocyte development, differentiation, activation, and aging. Immunol Rev. 1997;160: 43-54. (Pubitemid 28021365)
11. Roth A, Yssel H, Pene J, Chavez EA, Schertzer M, Lansdorp P, et al. Telomerase levels control the lifespan of human T lymphocytes. Blood. 2003;102;849-57. (Pubitemid 36917775)
12. 4+ T cells against NY-ESO-1. New Eng J Med. 2008;358:2698-703. (Pubitemid 351860862)
13. Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. 2011;29:917-24.
14. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubistein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205-16. (Pubitemid 30099779)
15. Turin I, Pedrazzoli P, Tullio C, Montini E, La Grotteria MC, Schiavo R, et al. GMP production of anti-tumor cytotoxic T-cell lines for adoptive T-cell therapy in patients with solid neoplasia. Cytotherapy. 2007;9:499-507. (Pubitemid 47386687)
16. Freshney RI. Induction of differentiation in neoplastic cells. Anticancer Res. 1985;5:111-6.
17. Montagna D, Schiavo R, Gibelli N, Pedrazzoli P, Tonelli R, Pagani S, et al. Ex vivo generation of anti-tumor cytotoxic T-cell lines derived from patients and their HLA-identical sibling. Int J Cancer. 2004;110:76-86. (Pubitemid 38507206)
18. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, et al. Specifi c association of human telomerase activity with immortal cells and cancer. Science. 1994;266: 2011 - 5.
19. Villa R, Folini M, Perego P, Supino R, Setti E, Daidone MG, et al. Telomerase activity and telomere length in human ovarian cancer and melanoma cell lines: Correlation with sensitivity to DNA damaging agents. Int J Oncol. 2000;16:995-1002.
20. Lisini D, Zecca M, Giorgiani G, Montagna D, Cristantielli R, Labirio M, et al. Donor/recipient mixed chimerism does not predict graft failure in children with beta-thalassemia given an allogeneic cord blood transplant from an HLAidentical sibling. Hematologica. 2008;93:1859-67.
21. Montagna D, Maccario R, Locatelli F, Rosti V, Yang Y, Farness P, et al. Ex vivo priming for long-term maintenance of antileukemia human cytotoxic T cells suggests a general procedure for adoptive immunotherapy. Blood. 2001;98: 3359-66.
22. Locatelli F, Comoli P, Montagna D, Rossi F, Daudt L, Maccario R. Innovative approaches of adoptive immune cell therapy in pediatric recipients of hematopoietic stem cell transplantation. Best Pract Res Clin Haematol. 2004;17: 479-92. (Pubitemid 39462578)
23. Kapp M, Rasche L, Einsle H, Grigoleit GU. Cellular therapy to control tumor progression. Curr Opin Hematol. 2009;16: 437-43.
24. Ebert LM, Schaerli P, Moser B. Chemokine-mediated control of T cell traffi c in lymphoid and peripheral tissues. Mol Immunol. 2005;42:799-809. (Pubitemid 40489029)
25. Rose DM, Alon R, Ginsberg MH. Integrin modulation and signaling in leukocyte adhesion and migration. Immunol Rev. 2007;218:126-34. (Pubitemid 47052306)
26. Stamenkovic I. The L-selectin adhesion system. Curr Opin Hematol. 1995;2:68-75.
27. Nagasawa TA. Chemokine, SDF-1/PBSF, and its receptor, CXC chemokine receptor 4, as a mediator of hematopoiesis. Int J Hematol. 2000;72:408-11.
28. Valenzuela HF, Effros RB. Divergent telomerase and CD28 expression patterns in human CD4 and CD8 T cells following repeated encounters with the same antigenic stimulus. Clin Immunol. 2002;105:117-25. (Pubitemid 35471660)
29. Rufer N, Dragowska W, Thornbury G, Roosnek E, Lansdorp PNM. Telomere length dynamics in human lymphocyte subpopulation measured by fl ow cytometry. Nat Biotechnol. 1998;16:743-7. (Pubitemid 28363755)
30. Shen X, Zhou J, Hatcock KS, Robbins P, Powell DJ Jr, Rosenberg SA, Hodes RJ. Persistence of tumor infi ltrating lymphocytes in adoptive immunotherapy correlates with telomere length. J Immunother. 2007;30:123-9. (Pubitemid 46052211)
31. Zhou J, Shen X, Huang J, Hodes RJ, Rosenberg SA, Robbins PF. Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. J Immunol. 2005;175: 7046-52. (Pubitemid 41598952)
32. Tran KQ, Zhou J, Durfl inger KH, Langhan MM, Shelton TE, Wunderlich JR, et al. Minimally cultured tumor-infi ltrating lymphocytes display optimal characteristics for adoptive cell therapy. J Immunother. 2008;31:742-51.